Significant Agreements - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 25, 2025 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Significant Agreements [Line Items] | |||||
| Cash payment related to warrants issued | $ 551 | $ 0 | |||
| Research and development expense | $ 261,499 | $ 21,823 | 288,200 | 46,145 | |
| Operating cash outflow | (66,250) | $ (52,312) | |||
| Telitacicept License Agreement | |||||
| Significant Agreements [Line Items] | |||||
| Research and development expense | $ 222,600 | ||||
| Operating cash outflow | (222,600) | ||||
| Regulatory milestone payments related to agreement | 330,000 | ||||
| Sales milestone payments related to agreement | 3,775,000 | ||||
| RemeGen Warrants | |||||
| Significant Agreements [Line Items] | |||||
| Amount of warrants issued | 177,400 | ||||
| RemeGen Warrants | Telitacicept License Agreement | |||||
| Significant Agreements [Line Items] | |||||
| Cash payment related to warrants issued | 45,000 | ||||
| Amount of warrants issued | 177,400 | ||||
| Warrant and rights payable | $ 45,000 | $ 45,000 | |||
| Transaction costs related to license agreement | $ 200 | ||||